Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines.

Literature DB >> 16361414

Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines.

Malachy Ifeanyi Okeke¹, Oivind Nilssen, Terje Traavik.

Abstract

Recombinant viruses based on modified vaccinia virus Ankara (MVA) are vaccine candidates against infectious diseases and cancers. Presently, multiplication of MVA has been demonstrated in chicken embryo fibroblast and baby hamster kidney (BHK-21) cells only. The multiplication and morphogenesis of a recombinant (MVA-HANP) and non-recombinant MVA strain in BHK-21 and 12 other mammalian cell lines have now been compared. Rat IEC-6 cells were fully permissive to MVA infection. The virus yield in IEC-6 cells was similar to that obtained in BHK-21 cells at low as well as high multiplicities of infection. Vero cells were semi-permissive to MVA infection. Mature virions were produced in supposedly non-permissive cell lines. The multiplication and morphogenesis of non-recombinant MVA and MVA-HANP were similar. These results are relevant to the production and biosafety of MVA-vectored vaccines.

Entities: Disease Species

Mesh：

Substances：
DNA, Viral

Year: 2006 PMID： 16361414 DOI： 10.1099/vir.0.81479-0

Source DB: PubMed Journal: J Gen Virol ISSN： 0022-1317 Impact factor: 3.891

Keyword Cloud
Cited

12 in total

1. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.

Authors: Christine Meisinger-Henschel; Michaela Späth; Susanne Lukassen; Michael Wolferstätter; Heike Kachelriess; Karen Baur; Ulrike Dirmeier; Markus Wagner; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal: J Virol Date: 2010-07-28 Impact factor: 5.103

2. Comparative sequence analysis of A-type inclusion (ATI) and P4c proteins of orthopoxviruses that produce typical and atypical ATI phenotypes.

Authors: Malachy Ifeanyi Okeke; Olayiwola A Adekoya; Ugo Moens; Morten Tryland; Terje Traavik; Øivind Nilssen
Journal: Virus Genes Date: 2009-10 Impact factor: 2.332

3. Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Authors: Sharon Melamed; Linda S Wyatt; Robin J Kastenmayer; Bernard Moss
Journal: Vaccine Date: 2013-08-06 Impact factor: 3.641

4. Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions.

Authors: Virginie Doceul; Michael Hollinshead; Adrien Breiman; Kathlyn Laval; Geoffrey L Smith
Journal: J Gen Virol Date: 2012-05-23 Impact factor: 3.891

Review 5. Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.

Authors: Martine Goossens; Katia Pauwels; Nicolas Willemarck; Didier Breyer
Journal: Curr Gene Ther Date: 2013-12 Impact factor: 4.391

6. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

Authors: Matthew G Cottingham; Rikke F Andersen; Alexandra J Spencer; Saroj Saurya; Julie Furze; Adrian V S Hill; Sarah C Gilbert
Journal: PLoS One Date: 2008-02-20 Impact factor: 3.240

7. In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.

Authors: Malachy Ifeanyi Okeke; Øivind Nilssen; Ugo Moens; Morten Tryland; Terje Traavik
Journal: Virol J Date: 2009-05-12 Impact factor: 4.099